Company intelligence / Profile preview
AC Immune SA
- Ownership
- Public · ACIU
- Employees
- ~133
- Development stage
- Other
Overview
AC Immune has a broad clinical pipeline with sixteen therapeutic and diagnostic programs targeting neurodegenerative diseases. The company has achieved multiple clinical milestones with five assets in Phase 2 trials and one asset advancing to Phase 3. Its technologies have been validated through major partnerships with pharmaceutical leaders such as Takeda, Janssen Pharmaceuticals (Johnson & Johnson), Eli Lilly & Co., and Life Molecular Imaging. Recent results include strong antibody responses for its active immunotherapy against alpha-synuclein in non-human primates.
- Therapeutic areas
- Neurology
- Modalities
- Active immunotherapies (vaccines)monoclonal antibodies (mAbs)small molecule drugsdiagnostic agents
- Industry
- Biotech
Drug pipeline
29 assets28 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $214.7M
- Total revenue
- $4.4M
- Enterprise value
- $127.6M
Beyond the preview
Go deeper on AC Immune SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AC Immune SA.